Clinical trial
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
NCT00479219 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00479219 |
|---|---|
| Title | Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients |
| Official title | A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug, Other |
| Interventions | GSI-953, Placebo |
| Enrollment | 17 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | May 28, 2007 |
| Last update posted | Jul 10, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: